However, BTK inhibitors have been extended to treat some of the solid tumors, such as non-small cell lung cancer, breast cancer, and pancreatic cancer (Zhang B. et al., 2019; Metzler et al., 2020), suggesting that BTK may affect other immune cells in various TMEs. The gene discussed is BTK; the disease is breast cancer.